SUMMARY
Bone marrow transplantation (BMT) has significant morbidity and mortality. Disease-free survival following BMT varies with the underlying disease and ranges from 90% for aplastic anaemia to much lower rates with malignancies such as acute myeloid leukaemia (failed induction 15-20%, first remission 55-60%) 1 . Complications and poor outcomes may result from: 1. toxicity of the conditioning regimen; 2. immunosuppression from marrow depletion, antirejection drugs and graft versus host disease (GVHD); 3. donor cell mediated toxicity as acute or chronic GVHD; 4. recipient cell mediated toxicity as graft rejection; and 5. relapse of the underlying malignancy. Pulmonary complications may require intensive care management and mechanical ventilation. The causes of pulmonary complications include infectious and non-infectious aetiologies. The latter include chemotherapy/radiation-induced toxicity, cytokine-mediated damage, pulmonary haemorrhage, cardiogenic pulmonary oedema, relapse of the malignancy, idiopathic syndromes and pre-transplant pulmonary pathology 1, 2 . Survival of BMT patients requiring mechanical ventilation is poor. During the 1980s, survival at six months post-BMT for patients requiring mechanical ventilation for longer than 24 hours was 3-5%. In contrast survival at six months post-BMT for nonventilated patients was greater than 70% 3, 4 . A more recent study spanning 1988-1993 found 15% survival to six months post-ventilation 5 . With improvements in the care of BMT patients and advances in the management of pulmonary complications, it is likely that survival will change over time. Thus, regular audits of outcome should be performed. The principal aims of this study were: 1. to determine the requirement for mechanical ventilation and subsequent survival of haematopoietic stem cell transplant (HSCT) recipients in an Australian institution, and 2. assess whether published outcome predictors could be applied to our patients.
MATERIALS AND METHODS
The Royal Brisbane Hospital is a tertiary referral hospital with a BMT unit and a general intensive care unit (ICU). Ethical permission for the study was granted under the institutional quality assurance guidelines. Case notes of all HSCT recipients requiring mechanical ventilation at this institution from January 1988 to December 1998 were reviewed. Patients ventilated for short periods (<24 hours) following minor procedures were excluded. Clinical data pertaining to the transplant and period of mechanical ventilation were extracted.
Survival was documented to ICU discharge, hospital discharge, 30 days post-ventilation and six months post-ventilation. Time spans were taken from cessation of mechanical ventilation.
Definitions
HSCT included BMT and peripheral blood stem cell transplants (PBSCT). Mechanical ventilation referred to machine assisted tidal breaths through an endotracheal tube. Recipient-donor compatibility was classified as matched sibling donor, or other. Neutropenia was defined as neutrophil count <0.5 x10 9 /l. The diagnosis and grading of GVHD is defined in the literature 2 . APACHE II was scored on the day of admission as defined in the literature 6 . Hepatic insufficiency was defined as serum bilirubin >68 mmol/l during the period of ventilation. Renal insufficiency was defined as occurring during the period of ventilation and serum creatinine >0.17 mmol/l; or urine output <400 ml/24 hours and patient died; or had dialysis initiated before serum creatinine rose to 0.17 mmol/l. Vasopressor use was defined as dopamine, noradrenaline or adrenaline infusions for more than four hours but excluded dopamine infusions <5 µg/kg/min. The predominant aetiology of respiratory failure was classified as infective, noninfective or unknown. Classification was resolved on the basis of recorded assessments of managing clinicians, retrospective review of case notes, and results of bronchoalveolar lavage. Infective included primary respiratory infections due to bacteria, viruses, pneumocystis carinii and other fungi. Noninfective included pulmonary haemorrhage, radiation-induced injury, drug-induced fibrosis, cardiogenic pulmonary oedema and the acute respiratory distress syndrome (ARDS) not due to respiratory infections. Haemodialysis included continuous and intermittent modes.
Statistics
Chi square and Fisher exact tests were used for subgroup analyses. A stepwise logistic regression model was constructed for predicting the risk of mechanical ventilation with input variables pertaining to the source of transplant. For statistical analyses, only first episodes of ventilation were considered. Stata Version 7 (Stats Corporation, College Station, Texas, USA) was used for statistical analysis.
RESULTS
From January 1988 to December 1998, 717 patients underwent a HSCT, comprising 420 BMT (80 autologous, 340 allogeneic) and 287 PBSCT (211 autologous, 76 allogeneic). Ten patients received both BMT and PBSCT, all of which were autologous. Admission to ICU was required by 56 HSCT recipients, of whom 50 met the study criteria. Of the six excluded patients, two were admitted for haemodiafiltration, one for respiratory failure that did not require ventilation and three after minor procedures requiring ventilation for less than 24 hours.
The 50 study patients comprised 42 BMT and eight PBSCT. Five patients were ventilated for more than 24 hours on two occasions. Noninvasive ventilation was administered to only two patients, both of whom subsequently required intubation.
Mechanical ventilation was required by 10.8% of allogeneic and 1.4% of autologous recipients (P<0.001). We constructed a stepwise logistic regression model for risk of undergoing mechanical ventilation with input variables pertaining to the source of the transplant: allogeneic versus autologous, and bone marrow versus peripheral blood stem cells. This showed allogeneic transplantation to be a risk factor (adj OR=6.7 CI 95=2.2-20.3) for mechanical ventilation that was independent of the transplant source being bone marrow or peripheral blood stem cells.
The median age of the group was 39 years (range 16-60). The underlying disease was a haematological malignancy in 96% and breast carcinoma in 4% of patients. The median transplant-ventilation interval was 64 days (range 5-1356 days). The median APACHE II score was 24 (range 14-47). Patients were ventilated for a median of 8 days (range 0.25-78). During the period of ventilation, 26% required haemodialysis (median duration four days, range 0.25 to 38 days), 52% received vasopressors (median four days, range 0.25 to 17 days), 60% had hepatic insufficiency, and 74% had renal insufficiency. At initiation of mechanical ventilation, 24% of patients were neutropenic.
The reason for ventilation was respiratory failure in 90% of patients, reduced level of consciousness in 8%, and post-laparotomy in 4% (one patient had both respiratory failure and a reduced level of consciousness). Of the 45 patients with respiratory failure leading to ventilation, the predominant aetiology was classified as infective in 15 patients, non-infective in 16 patients and uncertain in 14 patients. The 290 organisms responsible for infective respiratory failure were bacterial in 11, viral in three, fungal in two and Pneumocystis carinii in three. Five patients had two organisms identified. Of the patients without respiratory failure when ventilated (n=5), three subsequently developed respiratory complications (two non-infective and one uncertain) and one was admitted to ICU on a second occasion for respiratory failure of uncertain cause but was a long-term survivor.
Of HSCT recipients requiring mechanical ventilation, 28% survived to discharge from ICU, 20% to 30 days post-ventilation, 18% to hospital discharge and 12% to six months post-ventilation. Table 1 shows outcome according to subgroups. Survival was not significantly different for transplant source, gender, age, transplant-ventilation interval, reason for ventilation, cause of respiratory failure, presence of neutropenia, duration of ventilation, or subgrouping 1988-93 versus 1994-98. Survival at ICU discharge was significantly associated with APACHE II score >23, the presence of hepatic or renal insufficiency and the need for vasopressors or haemodialysis. At six months survival was no longer statistically significant for the need for vasopressors or haemodialysis but trends persisted. No patient who received haemodialysis survived ICU. Ventilated patients with a matched sibling donor had poorer early survival than those with less well matched donors. There was a trend to better early survival in patients with GVHD.
Details concerning the six patients surviving to six months post-ventilation are listed in Table 2 . All received allogeneic HSCTs. Their diagnostic groups were disparate. Notably, one patient received vasopressor therapy and another sustained both hepatic and renal insufficiency during a second episode of ventilation.
DISCUSSION
We found 12% of HSCT recipients receiving mechanical ventilation survived to six months postventilation. Crawford et al 3, 4, 7 reported the largest published series of BMT recipients requiring mechanical ventilation spanning 1980 to 1992. Survival to six months post-BMT was 3 to 5%. However, the range of transplant-ventilation intervals was considerably less than in our series. Survival rates from other studies in the 1980s were also poor [8] [9] [10] [11] [12] . However, studies of HSCT recipients needing mechanical ventilation in the 1990s reveal survival rates of 18% to ICU discharge 13 , 17-19% to hospital discharge 5, 14, 15 , and 5 to 15% to six months postventilation 5, 13 . These results are comparable with survival rates in our series of 28%, 18% and 12% to these three endpoints.
Large quantities of financial and emotional resources are expended to achieve the survival of this small group. Successful predictors of survival would be useful. The largest published series from Seattle 3, 4, 7 showed that once ventilated, survival was statistically [10] [11] [12] [13] , hepatic insufficiency 5, 15 , need for haemodynamic support 5 , presence of organ failure 12 , septic shock 12 and presence of GVHD 13 . However, some studies have shown no predictive value for some of these factors including age 5, [9] [10] [11] 13 , APACHE II score 9, 13 , use of vasopressors 9 , allogeneic transplantation [8] [9] [10] , and duration of ICU admission or mechanical ventilation 8, 9 . Many of these studies were hampered by small size.
In our study there was very poor survival for patients with APACHE II scores >23, and with organ failure as evidenced by the need for haemodialysis, the need for vasopressors, or the presence of hepatic or renal insufficiency. Indeed no patient who received haemodialysis survived to discharge from ICU. Other series have reported survival following haemodialysis 3 . The observation of poorer early survival in matched sibling donors and trend to better early survival with presence of GVHD may reflect differences in underlying pathology leading to mechanical ventilation, but may also be a result of the small number of patients in our study. The early differences were not sustained at six months.
There were six survivors at six months postventilation in our series ( Table 2 ). The reasons for ventilation included disparate infective and noninfective aetiologies. The transplant-ventilation intervals and durations of ventilation were quite variable. Rubenfeld and Crawford 7 found there were no survivors in the group of patients who had lung injury and either required more than four hours of vasopressor support or had sustained both hepatic and renal insufficiency. However, in our series, two of the long-term survivors met these criteria for nonsurvival. These results accentuate the difficulty of predicting survival for individual patients.
Recent studies have suggested a beneficial role for non-invasive ventilation in cancer and immunosuppressed patients with respiratory failure 16, 17 . Only two patients received such support in this series and both subsequently required intubation.
The proportion of BMT recipients receiving mechanical ventilation (9.8%) was considerably lower than in most other published series which are summarized in Table 3 . This discrepancy suggests dissimilar patient groups and differences in institutional practices regarding decisions concerning mechanical ventilation. It emphasizes the care needed in extrapolating findings from North American practice to the Australian setting.
We found recipients of autologous transplants to be less likely to require mechanical ventilation than recipients of allogeneic transplants (1.4% versus 10.8% respectively). This difference achieved a high level of statistical significance, but the conclusion is partly undermined by our study not determining how many patients developed respiratory failure and died without admission to ICU. Shorr et al 14 found 10.7% of recipients of autologous HSCT required mechanical ventilation, and noted this was significantly lower than published rates for recipients of BMT, the majority of which were allogeneic. Ho et al 18 found in the early post-BMT period that severe pulmonary complications (diffuse alveolar haemorrhage, need for mechanical ventilation or death from respiratory failure) occurred in 2.9% of autologous HSCT recipients compared with 24% of allogeneic HSCT recipients. Relevant differences between the autologous and allogeneic recipient include the latter experiencing GVHD with resultant immunosuppression and cytokine-mediated lung injury; the administration of immunosuppressant drugs to tolerate the graft; the possibility of graft rejection; and different underlying illnesses.
Price et al 15 looked at the separate issue of outcome once mechanical ventilation had occurred and concluded the source of the transplant being PBSCT or autologous favoured survival. Our study did not support these findings, but the numbers of ventilated PBSCT recipients (n=8) and autologous recipients (n=4) were small. This study has a number of limitations. The time span of the series was long. However, there was no significant difference in survival between the subgroups from 1988 to 1993 and 1994 to 1998. There was a large variation in the transplant-ventilation interval. Three studies have found a longer transplant-ventilation interval to be associated with a poorer outcome 7, 13, 15 , but one found the opposite 8 . It is thought some early aetiologies of respiratory failure such as pulmonary oedema and drug toxicities may have a better outcome. However, in our series, comparison of patients ventilated before and after 100 days post-transplant showed no significant differences in survival. We confirmed the presence of renal or hepatic dysfunction correlated with a poorer outcome, but did not assess the effect of chronicity of these pathologies. We found the determination of the principal aetiology of respiratory failure difficult, even in retrospect, as it required a delineation of the relative effects of multiple insults to the lung. Even patients with an infective aetiology for their respiratory failure were likely to have non-infective elements as well. Given these difficulties, it is not surprising published analyses of small groups of patients yield conflicting results concerning predictors of survival.
Diagnostic uncertainty also adds to the difficulty of treating these patients. Nonetheless, like us, many centres treat small numbers of such patients. It is reassuring that a centre dealing with a low frequency of HSCT patients can achieve outcomes comparable with the best published results.
CONCLUSIONS
Mechanical ventilation for HSCT recipients should not be regarded as futile therapy. Risk factors for mortality in the HSCT recipient receiving mechanical ventilation include renal, hepatic and cardiovascular insufficiency and greater severity of illness. However, as determinants of prognosis, these factors are not specific enough to allow decisions concerning futility of care for individuals. Recipients of autologous transplants are significantly less likely to require mechanical ventilation than recipients of allogeneic transplants.
